secwatch.observer — SEC 8-K summary
======================================

Issuer:     HAEMONETICS CORP (HAE)
CIK:        0000313143
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0000313143-25-000021
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Haemonetics approves restructuring $20M charges; targets $30M annual savings
----------------------------------------------------------------------------

- Board approved market and regional alignment initiative in May 2025.
- Expected aggregate restructuring charges of ~$20M, half severance, half other exit costs.
- Savings of ~$30M annually expected by end fiscal 2027.
- Q4 and FY 2025 earnings press released issued; no specific figures available in filing.
- Charges will be cash outlays; initiative to continue through fiscal 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/313143/000031314325000021/0000313143-25-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/313143/000031314325000021/hae-20250506.htm
  HTML page:      https://secwatch.observer/filing/0000313143-25-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer